临床外科杂志 ›› 2020, Vol. 28 ›› Issue (5): 472-475.doi: 10.3969/j.issn.1005-6483.2020.05.022

• • 上一篇    下一篇

前列腺癌骨转移病人唑来膦酸不同给药间期疗效比较

  

  1. 广州市第一人民医院(华南理工大学附属第二医院)综合外科
  • 出版日期:2020-05-20 发布日期:2020-05-20

Efficacy of zoledronic acid dosing every 12 VS 4 weeks in patients with bone metastases of prostate cancer

  • Online:2020-05-20 Published:2020-05-20

摘要: 目的:比较唑来膦酸在前列腺癌骨转移病人不同给药间期(4周及12周)临床疗效的差异.方法:前列腺癌骨转移病人52例,按治疗间期分为每4周1次组(A组)及每12周1次组(B组),给予4.0mg唑来膦酸静滴1年。比较两组病人治疗后骨相关事件(SRE)发生率,首次SRE发生时间、骨发病率、肌酐纠正的尿N末端肽、骨痛缓解、骨转移灶控制及不良反应相关情况。结果:A组中有64.0%、B组中有33.3%病人出现治疗拖延,两组间比较,差异有统计学意义(P<0.05)。A组中5例(20.0%)、B组中6例(22.2%)出现了至少1个SRE,两组间首次SRE时间均在30周左右出现,差异无统计学意义(P>0.05)。A、B组的平均骨发病率(SMR)值分别为0.46∶0.50,差异无统计学意义(P>0.05)。疼痛数字量表(NRS)评分及及止痛药用量各监测时间点均无明显差异(P>0.05)。肌酐纠正的尿N末端肽(uNTX/Cr)率仅在48周时B组高于A组,其他时间两组未有明显差异。骨转移灶缓解:24周及48周时骨扫描显示两组骨转移灶控制情况无明显差异。A组消化道反应和低血钾发生率高于B组,但差异无统计学意义(P>0.05)。结论:唑来膦酸每12周1次在缓解骨痛,控制骨进展效果不次于每4周1次,是前列腺骨转移病人可接受治疗方案。

关键词: 唑来膦酸, 骨转移, 前列腺癌

Abstract: Objective:To observe the treatment effect of zoledronic acid dosing every 12 VS 4 weeks in patients with prostate cancer metastatic to bone.Methods:52 patients with prostate cancer and bone metastases were assigned to receive 4.0mg of intravenous zoledronic acid every 4 (group A)or every 12 weeks (group B)for 1 year.The clinical value about twoway therapy were evaluated on SRE rate、first SRE and skeletal morbidity rate、uNTX/Cr ratio、bone pain relief rate、number of bone metastases and adverse events.Results:Treatment delay was observed in 64.0% of group A and 33.3% of group B,and the difference between the two groups was statistically significant(P<0.05).SREs occurred in 5 patients(20.0%)in group A and 6 patients(22.2%)in group B.The SREs rate and the time to first SRE(occured about 30 weeks)between two groups were not significantly different(P>0.05).The mean SMR was 0.46 vs 0.50 events per year in in group A and group B(P>0.05).The uNTX/Cr ratio had no statistical difference between the 2 treatment groups in each time period(P>0.05),except at the 48 weeks.Bone pain relief rate of two groups was not statistically significant in each time point.Adverse events:In group A,the proportion of patients in digestive tract reaction and hypopotassemia was higher than another group.But all AEs in two groups had no statistical difference.Conclusion:The every 12 weeks regimen of zoledronic acid was noninferior to the every 4 weeks regimen for treatment of patients with bone metastasis from prostate cancer in relief bone pain and control the progression of bone lesions.This longer interval may be an acceptable treatment option.

Key words: zoledronic acid, bone metastases, prostate cancer

[1] 刘大乐 肖克峰 刘岩峰 刘增钦 黄建生. 腹腔镜前列腺癌根治术对前列腺癌病人的疗效及对转化生长因子-β1、转化生长因子-β3及前列腺特异性抗原水平的影响[J]. 临床外科杂志, 2020, 28(4): 374-377.
[2] 霍振清, 罗后宙, 梁冰等. miR-375,EPCA-2联合PSA对早期前列腺癌的诊断价值研究[J]. 临床外科杂志, 2019, 27(9): 809-812.
[3] 李维, 黄永超. 经皮微创内固定联合术后唑来膦酸治疗胸腰椎骨折的疗效及对T细胞亚群的影响[J]. 临床外科杂志, 2019, 27(4): 345-348.
[4] 庞松强, 罗功唐, 宋瑶. 3D与2D腹腔镜前列腺癌根治术治疗前列腺癌综合效果及并发症比较[J]. 临床外科杂志, 2019, 27(2): 109-112.
[5] 曾卫锋. 碳酸酐酶9检测对前列腺癌预后评估的临床意义 [J]. 临床外科杂志, 2013, 21(3): 209-211.
[6] 刘修恒 郭佳 . 前列腺癌的微创治疗 [J]. 临床外科杂志, 2013, 21(2): 86-88.
[7] 赵立. 前列腺癌的Gleason评分及临床意义[J]. 临床外科杂志, 2012, 20(2): 87-87.
[8] 程跃 严泽军. 前列腺癌的试验性局部治疗[J]. 临床外科杂志, 2012, 20(2): 84-84.
[9] 王少刚 王志华. 前列腺癌的腔镜治疗[J]. 临床外科杂志, 2012, 20(2): 81-81.
[10] 翁志梁. 前列腺癌骨转移机理及治疗[J]. 临床外科杂志, 2012, 20(2): 77-77.
[11] 王志平 张耘新. 间歇性内分泌治疗前列腺癌[J]. 临床外科杂志, 2012, 20(2): 73-73.
[12] 祝强. 雌激素与前列腺疾病的研究进展[J]. 临床外科杂志, 2011, 19(8): 571-571.
[13] 杨川. PCA3mRNA与PSAmRNA的联合检测对前列腺癌早期诊断的临床意义[J]. 临床外科杂志, 2011, 19(8): 569-569.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!